MOSHE ROSE: Open Payments
NPI 1982765574 · NEWARK, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$639 in 37 payments from 10 companies in 2025. Trend: 2023 $583 · 2024 $585 · 2025 $639
Food & beverage: $640
| Company | Payments | Amount |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 11 | $152 |
| Otsuka America Pharmaceutical, Inc. | 11 | $139 |
| Biogen, Inc. | 1 | $120 |
| ABBVIE INC. | 4 | $70 |
| Alkermes, Inc. | 4 | $63 |
| E.R. Squibb & Sons, L.L.C. | 2 | $33 |
| Vanda Pharmaceuticals Inc. | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Lundbeck LLC | 1 | $14 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $14 |
Products named: Qelbree, REXULTI, ZURZUVAE, VRAYLAR, ARISTADA, COBENFY, ABILIFY ASIMTUFII, FANAPT.
Industry payments across NJ — which companies pay providers there.
